| RÁZGA, Filip, Tomáš JURČEK, Daniela ŽÁČKOVÁ, Dana DVOŘÁKOVÁ, Martina TOŠKOVÁ, Ivana JEŽÍŠKOVÁ, Jiří MAYER a Zdeněk RÁČIL. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. Molecular diagnosis and therapy. Adis, 2012, roč. 16, č. 4, s. 251-259. ISSN 1177-1062. |
Další formáty:
BibTeX
LaTeX
RIS
@article{988780,
author = {Rázga, Filip and Jurček, Tomáš and Žáčková, Daniela and Dvořáková, Dana and Tošková, Martina and Ježíšková, Ivana and Mayer, Jiří and Ráčil, Zdeněk},
article_number = {4},
keywords = {BCR-ABL1; gene mutations; CML},
language = {eng},
issn = {1177-1062},
journal = {Molecular diagnosis and therapy},
title = {Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations},
volume = {16},
year = {2012}
}
TY - JOUR
ID - 988780
AU - Rázga, Filip - Jurček, Tomáš - Žáčková, Daniela - Dvořáková, Dana - Tošková, Martina - Ježíšková, Ivana - Mayer, Jiří - Ráčil, Zdeněk
PY - 2012
TI - Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations
JF - Molecular diagnosis and therapy
VL - 16
IS - 4
SP - 251-259
EP - 251-259
PB - Adis
SN - 11771062
KW - BCR-ABL1
KW - gene mutations
KW - CML
N2 - Our data show that pretreatment with non-specific non-TKI drugs prior to TKI therapy does not preferentially select for initial BCR-ABL1 KD mutations, in contrast to first-line imatinib therapy, which shows a clear predominance of T315I or P-loop mutations compared with mutations located in other KD regions. In addition, the median time to detection of P-loop mutations was substantially shorter in patients treated with first-line imatinib than in those pretreated with non-TKI drugs. Furthermore, analysis of CML patients who had recurrent resistance to TKI therapy revealed possible therapy-driven selection of BCRABL1 KD mutations. Finally, we confirm the previously described poor prognosis of CML patients with mutations in the BCR-ABL1 KD, since 40.0% of our CML patients who harbored a BCR-ABL1 KD mutation died from CML while receiving TKI treatment. Moreover, among the patients who are still on treatment, 27.8%have already progressed. Our data also confirm the unique position of the T315I mutation with respect to its strong resistance to currently approved TKIs.
ER -
RÁZGA, Filip, Tomáš JURČEK, Daniela ŽÁČKOVÁ, Dana DVOŘÁKOVÁ, Martina TOŠKOVÁ, Ivana JEŽÍŠKOVÁ, Jiří MAYER a Zdeněk RÁČIL. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. \textit{Molecular diagnosis and therapy}. Adis, 2012, roč.~16, č.~4, s.~251-259. ISSN~1177-1062.
|
